Cellectar secures 'extended partnership' to support clinical trial needs

29-Nov-2016 - Last updated on 29-Nov-2016 at 15:24 GMT

(Image: iStock/shironosov)

Cellectar Biosciences has announced a partnership with the Centre for Probe Development and Commercialization (CPDC) to establish manufacturing capacity ahead of the company’s NCI-supported Ph II trial of CLR 131.

Per the agreement, the GMP manufacturing organization, which specializes in radiopharmaceuticals, will serve as a supplier of Cellectar’s lead phospholipid drug conjugate (PDC), CLR 131.

“CPDC possesses a great team and extensive experience manufacturing radiotherapeutics,” Jim Caruso, president and CEO of Cellectar Biosciences, told us, adding that the company will provide “cost effective, high quality finished product manufacturing for the long term.”

“This partnership will provide additional supply of CLR 131 and insure sufficient manufacturing capacity to support Cellectar’s near term clinical trial needs as well as pivotal study and larger scale commercialization requirements,” he added.

When asked how long the partnership is set to last, Caruso said “Cellectar looks forward to an extended partnership with CPDC.”

The next steps for the partnership include ongoing process integration and enhancement.